Michael Ciesielski

Michael Ciesielski

Company: MimiVax

Job title: Chief Executive Officer


Disrupting Glioblastoma: Survaxm Immunotherapy And Surviving Targeting Platforms 3:45 pm

• SurVaxM is a novel cancer vaccine designed to stimulate an immune response targeting the tumor-specific antigen surviving • A multi-center, single-arm phase 2a clinical trial of SurVaxM in survivinpositive newly diagnosed glioblastoma (nGBM, NCT02455557) is now complete • Newly diagnosed glioblastoma patients were followed for safety, 6-month progression-free survival (PFS6), 12-month overall survival (OS12)…Read more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.